Abstract 85P
Background
Treatment recommendations and benefit of local therapy in oligometastatic disease (OMD) are an era of interest and debate; however, it’s quite difficult to plan RCTs including patients with metastases due to ethical considerations as patients may lose an effective treatment if they are assigned to a control arm, furthermore, most of the clinical literature on OMD is cancer site specific, this study included OMD of different solid tumors.
Methods
In this observational prospective cohort study Patients with stage IV solid tumors who met the criteria of OMD (≤5 metastatic lesions, and or ≤2 organs) with performance status 0-2 were eligible; we studied disease characteristics and outcomes regarding local therapies of OMD.
Results
Two hundred and thirty-four patients with solid tumors met the criteria of OMD, 126 (53.8%) Patients received local therapies; surgery, Radiotherapy (RT), local ablative therapy (group I) and 108 (46.2%) Patients didn’t receive local therapy (group II). Comparing both groups, Group I: patients had significantly younger age, earlier initial TNM stage, higher rates of metachronous onset, symptomatic disease, soft tissue disease, single lesion and or single organ involvement and complete response, but lower rates of managed pulmonary OMD compared to group II. However, no significant association with specific primary cancer site, histological grade, molecular subtype, SUV activity level in PET/CT, type and number of systemic therapy lines, type of OMD (genuine vs. induced and repeated vs. de novo), cut of point of serum tumor markers or any subsequent delay of systemic treatment were noticed with local therapy (p value >0.05) and unexpectedly metastatic size of ≥ 3 cm was more amenable for local therapy (p value ≤0.05). Regarding survival, local therapy of OMD was associated with better PFS and OS: The mean OS in local therapy group was 64 months vs. 38 months in non local therapy patients and the median PFS was not reached in local therapy patients vs. 30 months in no local therapy patients. By multivariate regression analysis; local therapy for OMD is an independent prognostic factor for both PFS and OS.
Conclusions
For selected oligometastatic solid tumor patients, local therapy for OMD could improve PFS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract